AMPICILLIN FOR INJECTION, USP 250 MG
AMPICILLIN (AMPICILLIN SODIUM) : 250 MG · DIN 02227029 · FRESENIUS KABI CANADA LTD
Health Canada status: MARKETED
What is AMPICILLIN FOR INJECTION, USP?
AMPICILLIN FOR INJECTION, USP 250 MG contains AMPICILLIN (AMPICILLIN SODIUM) : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02227029, held by FRESENIUS KABI CANADA LTD, supplied as POWDER FOR SOLUTION for INTRAMUSCULAR ; INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 16-Aug-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is AMPICILLIN FOR INJECTION, USP called?
The same molecule, AMPICILLIN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| AMPICILLIN ARDEZ | Latin | Czechia |
| AMPICILIN BBP | Latin | Czechia |
| EPICOCILLIN | Latin | Bahrain |
| Petercillin | Latin | South Africa |
| AMPICILIN AVMC | Latin | Czechia |
| Ampouleipen | Latin | South Africa |
| Be-Ampicil | Latin | South Africa |
| Be-Ampouleicil | Latin | South Africa |
| Cloxam | Latin | South Africa |
| Megamox | Latin | South Africa |
| Megamox S | Latin | South Africa |
| Megapen S | Latin | South Africa |
| Novactam | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02227029 |
|---|---|
| Brand name | AMPICILLIN FOR INJECTION, USP |
| Generic / active ingredient | AMPICILLIN (AMPICILLIN SODIUM) : 250 MG |
| Manufacturer | FRESENIUS KABI CANADA LTD |
| Strength | 250 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAMUSCULAR ; INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J01CA01 AMPICILLIN |
| AHFS class | 08:12.16.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-Aug-2019 |
| Original market date | 1998-08-14 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02227029 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2227029 |
| Brand name | AMPICILLIN FOR INJECTION, USP |
| Active ingredient / INN | AMPICILLIN (AMPICILLIN SODIUM) : 250 MG |
| ATC code | J01CA01 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01 |
| AHFS class | 08:12.16.08 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | FRESENIUS KABI CANADA LTD |
Which pack is which?
| Strength on the label | 250 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAMUSCULAR ; INTRAVENOUS |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Is AMPICILLIN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by TEVA CANADA LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01CA01 AMPICILLIN. 17 of 56 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AMPICILLIN FOR INJECTION, USP | 1 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02227002 |
| AMPICILLIN FOR INJECTION, USP | 2 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02226995 |
| AMPICILLIN FOR INJECTION, USP | 500 MG | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02227010 |
| AMPICILLIN SODIUM FOR INJECTION BP | 1 G | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | DIN 02462338 |
| AMPICILLIN SODIUM FOR INJECTION BP | 1 G | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02530503 |
| AMPICILLIN SODIUM FOR INJECTION BP | 2 G | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | DIN 02462346 |
| AMPICILLIN SODIUM FOR INJECTION BP | 2 G | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02530511 |
| AMPICILLIN SODIUM FOR INJECTION BP | 250 MG | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | DIN 02462303 |
| AMPICILLIN SODIUM FOR INJECTION BP | 500 MG | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02530481 |
| AMPICILLIN SODIUM FOR INJECTION BP | 500 MG | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | DIN 02462311 |
Who else supplies AMPICILLIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. AMPICILLIN appears in 1362 registered pack listings across 7 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does AMPICILLIN cost around the world?
AMPICILLIN is listed on 7 national price registers Nexara tracks, across 84 pack listings published on 7 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Romania | max producer price | 14 | 34 | 03 Sep 2026 |
| South Africa | single exit price | 17 | 24 | 01 Sep 2026 |
| Saudi Arabia | public | 12 | 12 | 01 Sep 2026 |
| Czechia | max producer price (ex-factory) | 3 | 6 | 03 Sep 2026 |
| Greece | producer price (ex-factory) | 3 | 3 | 03 Sep 2026 |
| United States | acquisition | 1 | 3 | 03 Sep 2026 |
| Bahrain | retail (max) | 1 | 2 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.